Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -91.66% is 208% below its 5-year average of -29.79%, near the low end of its 5-year range (-91.66%–-9.42%).
88.23% below its 12-month average of -48.70%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -22.04%.
RETURN ON ASSETS (ROA)
-91.66%
RETURN ON ASSETS (ROA) AVG TTM
-48.70%
RETURN ON ASSETS (ROA) AVG 3Y
-37.97%
RETURN ON ASSETS (ROA) AVG 5Y
-29.79%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-88.23%
CURRENT VS 3Y AVG
-141.43%
CURRENT VS 5Y AVG
-207.70%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.70%
median of 715 covered companies
CURRENT VS SECTOR MEDIAN
-198.57%
vs the sector median at left
PMV Pharmaceuticals, Inc.
Market Cap
$90.66M
Return on Assets (ROA)
-91.66%
TTM Avg
-48.70%
3Y Avg
-37.97%
5Y Avg
-29.79%
Market Cap
$90.54M
Return on Assets (ROA)
46.45%
TTM Avg
-49.63%
3Y Avg
-50.17%
5Y Avg
-40.85%
Market Cap
$90.73M
Return on Assets (ROA)
-30.70%
TTM Avg
-50.88%
3Y Avg
-51.94%
5Y Avg
-48.05%
Market Cap
$91.83M
Return on Assets (ROA)
-169.86%
TTM Avg
-100.47%
3Y Avg
-69.80%
5Y Avg
-64.10%
Market Cap
$88.48M
Return on Assets (ROA)
1.69%
TTM Avg
-3.62%
3Y Avg
-6.49%
5Y Avg
-4.78%
Market Cap
$93.22M
Return on Assets (ROA)
-86.56%
TTM Avg
-66.44%
3Y Avg
-84.84%
5Y Avg
-75.69%
Market Cap
$93.63M
Return on Assets (ROA)
-88.24%
TTM Avg
-139.34%
3Y Avg
-100.15%
5Y Avg
-71.92%
Market Cap
$93.80M
Return on Assets (ROA)
-1.90%
TTM Avg
1.32%
3Y Avg
1.93%
5Y Avg
1.93%
Market Cap
$86.90M
Return on Assets (ROA)
8.52%
TTM Avg
11.64%
3Y Avg
-8.81%
5Y Avg
-6.61%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | $90.66M | -91.66% | -48.70% | -37.97% | -29.79% |
| Rallybio Corporation (RLYB)vs › | $90.54M | 46.45% | -49.63% | -50.17% | -40.85% |
| Equillium, Inc. (EQ)vs › | $90.73M | -30.70% | -50.88% | -51.94% | -48.05% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $91.83M | -169.86% | -100.47% | -69.80% | -64.10% |
| ImmuCell Corporation (ICCC)vs › | $88.48M | 1.69% | -3.62% | -6.49% | -4.78% |
| electroCore, Inc. (ECOR)vs › | $93.22M | -86.56% | -66.44% | -84.84% | -75.69% |
| Biomea Fusion, Inc. (BMEA)vs › | $93.63M | -88.24% | -139.34% | -100.15% | -71.92% |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $93.80M | -1.90% | 1.32% | 1.93% | 1.93% |
| CareCloud, Inc. (CCLD)vs › | $86.90M | 8.52% | 11.64% | -8.81% | -6.61% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $86.81M | -79.38% | 41.63% | -36.06% | -44.84% |
ROA
-91.7%
ROE
-105.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -66.70% |
| 2024-12-31 | -30.69% |
| 2023-12-31 | -27.35% |
| 2022-12-31 | -27.12% |
| 2021-12-31 | -17.45% |
| 2020-12-31 | -9.42% |
| 2019-12-31 | -24.61% |
| 2018-12-31 | -27.64% |
